HIV-1 Seroconversion Incidence Following Pregnancy and Delivery Among Women Seronegative at Recruitment in Harare, Zimbabwe
Overview
Authors
Affiliations
Objective: To estimate the incidence of HIV seroconversion among women following pregnancy and delivery.
Design: A prospective cohort of women who were HIV negative at recruitment on first antenatal care visit.
Materials And Methods: Pregnant women were invited to undergo voluntary confidential HIV counselling and blood draw for HIV testing during the first antenatal care visit as part of a prospective study of mother-to-child transmission of HIV-1. Repeat tests were conducted at delivery, six weeks post partum and at three monthly intervals until 24 months or on termination due to subsequent pregnancy, death or loss to follow up. Logistic regression modelling was used to determine independent predictors of HIV seroconversion.
Results: Among 372 HIV negative pregnant women who were enrolled, 66 seroconverted during follow up, resulting in a sero-incidence of 4.8 per 100 person years (95% confidence interval [CI], 3.1 to 6.5). Women who did not seroconvert during the time of pregnancy or follow up were significantly more likely to have used a condom with their partners (OR = 0.68, 95% CI = 0.47 to 0.99). Women aged 17 years and below had the highest seroconversion incidence (6.25%) followed by those aged 18 to 19 years (5.42%). Women who seroconverted and those who were HIV positive at recruitment were more likely to be married. Lack of education by the partner of a pregnant woman constituted a significant risk factor for HIV seroconversion (OR = 2.8; 95% CI = 1.1 to 11.0).
Conclusions: There is a high HIV seroconversion incidence among women during pregnancy and following delivery, especially those aged 19 years and below. Being married does not protect the women from the risk of HIV seroconversion. Strategies for HIV prevention should target pregnant women and their partners.
Dessale D, Gebremariam M, Wolde A Front Reprod Health. 2024; 6:1246734.
PMID: 38660333 PMC: 11039893. DOI: 10.3389/frph.2024.1246734.
Dugdale C, Ufio O, Alba C, Permar S, Stranix-Chibanda L, Cunningham C J Int AIDS Soc. 2023; 26(1):e26052.
PMID: 36604316 PMC: 9816086. DOI: 10.1002/jia2.26052.
Pregnancy associates with alterations to the host and microbial proteome in vaginal mucosa.
Farr Zuend C, Tobin N, Vera T, Kotyrba L, Noel-Romas L, Birse K Am J Reprod Immunol. 2020; 83(6):e13235.
PMID: 32196803 PMC: 7317380. DOI: 10.1111/aji.13235.
Graybill L, Kasaro M, Freeborn K, Walker J, Poole C, Powers K AIDS. 2020; 34(5):761-776.
PMID: 32167990 PMC: 7275092. DOI: 10.1097/QAD.0000000000002487.
Adinan J, Adamou B, Amour C, Shayo A, Kidayi P, Msuya L BMC Public Health. 2020; 19(1):1758.
PMID: 31888642 PMC: 6937982. DOI: 10.1186/s12889-019-8111-4.